Resources Repository
-
ArticlePublication 2017Revealed Willingness-to-Pay vs. Standard Cost-Effectiveness Thresholds
This study estimates the cost-effectiveness thresholds (CETs) of 16 HIV programs in South Africa. The …
This study estimates the cost-effectiveness thresholds (CETs) of 16 HIV programs in South Africa. The use of CETs based on a country’s income per capita has been criticized for not being grounded in theory or evidence, especially in low and middle-income countries (LMICs). An alternative has been produced for South Africa, based on estimates of life years saved and the country’s committed HIV budget. The authors used a previously -published optimization method to estimate CETs,…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Health/Medicine -
ArticlePublication 2017Estimated Economic Impact of Vaccinations in 73 LMIC, 2001-2020
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 …
This analysis estimates the economic impact likely to be achieved by efforts to vaccinate against 10 vaccine-preventable diseases between 2001 and 2020 in 73 low- and middle-income countries largely supported by Gavi, the Vaccine Alliance. The authors used health impact models to estimate the economic impact of achieving forecasted coverages for vaccination against Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae and yellow fever. In…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Health Outcomes | State-Transition | Dynamic Transmission | Microsimulation | Child/Nutrition | Health Systems | Health/Medicine | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Extended CEA: Diarrhea and Pneumonia in Ethiopia
This chapter examines universal public finance of the prevention and treatment of pneumonia and diarrhea …
This chapter examines universal public finance of the prevention and treatment of pneumonia and diarrhea in Ethiopia, with a focus on children under age five years. This extended cost-effectiveness analysis examines benefits by income quintile so that policy makers can better understand how each package affects different segments of the population and permits the incorporation of financial risk protection in the economic evaluation of health policies - both critical elements of universal health coverage.
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Health Outcomes | Child/Nutrition | Social Determinants | Health Systems | Health/Medicine -
ArticlePublication 2015Extended Cost-Effectiveness Analysis of Treatment and Prevention of Diarrhoea in Ethiopia
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits …
This article, published in BMJ Open, aims to illustrate the size and distribution of benefits due to the treatment and prevention of diarrhoea (i.e., rotavirus vaccination) in Ethiopia. The authors use an economic model to examine the impacts of universal public finance (UPF) of diarrhoeal treatment alone, as opposed to diarrhoeal treatment along with rotavirus vaccination using extended cost-effectiveness analysis (ECEA). The study finds that diarrhoeal treatment paired with rotavirus vaccination is more cost effective…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Health Outcomes | Child/Nutrition | Social Determinants | Environmental Health | Health Systems | Climate/Environment | Health/Medicine -
ArticlePublication 2015Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from Extended CEA
This article, published in PLOS ONE, conducts an extended cost-effectiveness analysis (ECEA) of two fully …
This article, published in PLOS ONE, conducts an extended cost-effectiveness analysis (ECEA) of two fully publicly financed interventions in Ethiopia: pneumococcal vaccination for newborns and pneumonia treatment for under-five children. The authors apply ECEA methods and estimate the program impact on: (1) government program costs; (2) pneumonia and pneumococcal deaths averted; (3) household expenses related to pneumonia/pneumococcal disease treatment averted; (4) prevention of household medical impoverishment; and (5) distributional consequences across the wealth strata of…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Costing Methods | Child/Nutrition | Social Determinants | Health Systems | Health/Medicine -
ArticlePublication 2013Public Finance of Rotavirus Vaccination in India and Ethiopia: Extended CEA
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for …
This study uses extended cost-effectiveness analysis (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. The authors measured program impact on: (1) averted rotavirus deaths; (2) reduction in household expenditures; (3) financial risk protection; and (4) distributional consequences across the country’s wealth strata. In India and Ethiopia, the program was predicted to decrease rotavirus deaths substantially, and effectively provide financial risk protection among the poor, while also reducing household…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Priority Setting/Ethics | Health Outcomes | Child/Nutrition | Social Determinants | Culture/Society | Health/Medicine | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Cost-Effectiveness Analysis | Economics/Finance | Sub-Saharan Africa | Infectious Diseases | Microsimulation | Calibration/Validation | Chronic Disease/Risk | Clinical Care | Health/Medicine | Science/Technology